The present disclosure provides a special culture apparatus for a 3D biological tissue, and a method for preparing block-shaped cultured meat. The special culture apparatus for a 3D biological tissue includes: a 3D biological tissue culture tank for accommodating a 3D biological tissue, and a liquid storage tank for containing a culture medium; the 3D biological tissue culture tank is connected to the liquid storage tank by means of a pipeline to form a circuit for the culture medium to circularly flow; and an opening of the 3D biological tissue culture tank is provided with a sealing plug, an inner side of the sealing plug is provided with a plurality of culture medium infusion needles that penetrate the 3D biological tissue when in use.

The present invention provides animal cells that have been engineered to express one or more viral antigens. The engineered cells can be formulated into cultured meat products that can be used as edible vaccines.

The invention relates to method for cultivating stem cells in vitro, comprising the following steps: providing a sample comprising stem cells and cultivating the stem cells by subjecting the sample to a treatment for a first period of time. The treatment is carried out under hypothermic conditions having a defined temperature and a defined atmosphere, wherein the temperature does not exceed 15° C. and the atmosphere has an oxygen content not exceeding 21% (v/v). Thereby, the first period of time is 4 days to 4 weeks.

The invention relates to method for cultivating stem cells in vitro, comprising the following steps: providing a sample comprising stem cells and cultivating the stem cells by subjecting the sample to a treatment for a first period of time. The treatment is carried out under hypothermic conditions having a defined temperature and a defined atmosphere, wherein the temperature does not exceed 15° C. and the atmosphere has an oxygen content not exceeding 21% (v/v). Thereby, the first period of time is 4 days to 4 weeks.

The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone). Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age.

The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone) when combined with a biocompatible matrix, preferably SIS. The invention further provides methods of using compositions comprising muscle-derived progenitor cells with a biocompatible matrix for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age.

The present invention provides muscle-derived progenitor cells (MDCs) that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction into a site of soft tissue. Also provided are methods of isolating MDCs. The invention further provides methods of using compositions comprising MDCs for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. The invention also relates to uses of MDCs for the treatment of cosmetic or functional conditions, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia. The invention also relates to the novel use of MDCs for the increase of skeletal muscle.

The invention is directed to methods and compositions for obtaining uniform sized muscle fiber fragments for transplantation. These muscle fiber fragments are able to reconstitute into long fibers that are oriented along native muscle. The implanted muscle cells integrate with native vascular and neural network, as confirmed by histology and immunohistochemistry. This invention is particularly advantageous because autologous muscle can be harvested from a donor site, processed and injected into target sites in the operating room. The fragmented muscle fibers can be readily integrated within the host.

The present disclosure provides methods of generating skeletal muscle progenitor cells (SMPCs). The present disclosure provides methods of generating immature SMPCs and multinucleated muscle cells, and matured SMPCs and multinucleated muscle cells. The present disclosure provides engraftment methods and treatment methods, involving generating SMPCs and introducing the SMPCs into an individual.

The present invention is directed to, inter alia, a scaffold-cell construct including a biocompatible polymer (e.g., poly-l-lactic acid (PLLA) and polylactic glycolic acid (PLGA)) and recombinant cells having increased GLUT4 levels and/or activity. The invention is further directed to methods for reducing glucose levels in a subject in need thereof. Also provided are methods of producing the scaffold-cell construct of the invention.